MSI-H cancer – what has happened in the last year?

Abstract

Currently, immunotherapy holds one of the leading positions in clinical practice. One of the predictive factors is the molecular phenotype of tumors with microsatellite instability features. Clinical trials demonstrate the high effectiveness of checkpoint inhibitors in this subgroup in terms of achieving an objective response, its duration, progression free survival, and overall survival. Such results encourage the use of immunotherapeutic approaches at early stages of the disease with the potential to cure this patient’s population.